Related Experiment Video
Updated: Jun 21, 2025
06:34
Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model
Published on: June 2, 2023
1.1K
Exercise to Counteract Alzheimer's Disease: What Do Fluid Biomarkers Say?
Roberto Bonanni1, Ida Cariati2, Pierangelo Cifelli3
1Department of Biomedicine and Prevention, "Tor Vergata" University of Rome, 00133 Rome, Italy.
International Journal of Molecular Sciences
|July 13, 2024
Summary
This review examines Alzheimer's disease (AD) fluid biomarkers and exercise effects. It clarifies exercise
Area of Science:
- Neuroscience
- Biochemistry
- Gerontology
Background:
- Neurodegenerative diseases, particularly Alzheimer's disease (AD), are a growing global health concern.
- AD is characterized by beta-amyloid (Aβ) and Tau protein accumulation, leading to neuronal death and cognitive decline.
- Fluid biomarkers are crucial for AD diagnosis and monitoring disease progression.
Purpose of the Study:
- To review key fluid biomarkers for Alzheimer's disease.
- To critically analyze the modulatory effects of exercise on these biomarkers.
- To clarify the efficacy of exercise as a non-pharmacological strategy for AD.
Main Methods:
- Literature review of studies on AD fluid biomarkers.
- Analysis of research investigating exercise interventions in AD patients.
- Synthesis of evidence regarding exercise's impact on biomarker concentrations.
Main Results:
- Conflicting results exist regarding exercise's effect on AD fluid biomarkers.
- Further research is needed to establish clear correlations and mechanisms.
- Exercise shows potential as an adjunct therapy for managing AD.
Conclusions:
- The role of exercise in modulating AD fluid biomarkers requires further elucidation.
- Understanding these effects is vital for optimizing non-pharmacological AD management.
- Exercise may help counteract neurodegeneration and cognitive decline in AD patients.
Related Concept Videos
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:22Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
01:20Exercise and Cardiovascular Response
775
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
775